Crohn's Disease Clinical Trial
Struggling to manage your Crohn's Disease?
You may be eligible for a clinical trial.
Struggling to manage your Crohn's Disease? You may be eligible for a clinical trial.
Recruiting Athens, GRC 10676
Recruiting Athens, GRC 11527
Details for the study
Treatments and/or Procedures
Inclusion Criteria: - Male or female aged >=18 to <= 80 years, or minimum age of adult consent according to local regulations, at the Baseline Visit. Where locally permissible, subjects 16 to < 18 years of age who meet the definition of Tanner stage 5 for development at the Baseline Visit - Diagnosis of CD for at least 3 months prior to Baseline - Confirmed diagnosis of moderate to severe CD as assessed by stool frequency (SF), abdominal pain (AP) score, and Simple Endoscopic Score for Crohn's Disease (SES-CD) - Demonstrated intolerance or inadequate response to biologic therapy for CD - If female, subject must meet the contraception recommendations Exclusion Criteria: - Subject with a current diagnosis of ulcerative colitis or indeterminate colitis - Subjects with unstable doses of concomitant Crohn's disease therapy - Receipt of Crohn's disease approved biologic agents (infliximab, adalimumab, certolizumab, vedolizumab, natalizumab within 8 weeks prior to Baseline or ustekinumab within 12 weeks prior to Baseline), or any investigational biologic or other agent or procedure within minimally 35 days or 5 half-lives prior to Baseline, whichever is longer. - Prior exposure to p19 inhibitors (e.g., risankizumab). - Complications of Crohn's disease (strictures, stenosis, short bowel, etc) - Having an ostomy or ileoanal pouch